We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 66.26+2.9%4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen8/17/2006 10:52:27 AM
   of 347
GenoMed's Second Horse Recovers Quickly from Presumed West Nile Virus Encephalitis

David W. Moskowitz MD - GenoMed - St. Louis, Missouri - Tel. 314.983.9933 -
Randy Bean DVM - Owyhee Veterinary Clinic - Homedale, Idaho - Tel. 208-337-4677

ST. LOUIS—August 17, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company that uses genomics to solve diseases in as many species as possible, today announced that the second horse in its expanded trial for West Nile virus encephalitis recovered completely within 72 hours after starting GenoMed's treatment.

On Saturday afternoon this past weekend, a horse owner in Idaho telephoned Dr. Randy Bean to say that his horse could no longer walk straight. The horse had not been vaccinated for West Nile virus, and the diagnosis was presumed West Nile virus encephalitis. The usual treatment for a horse with WNV costs about $700, and includes antiserum and intravenous dexamethasone. The owner didn't want to spend that much money on his horse. Dr. Bean, who had recently treated another horse with GenoMed's approach, encouraged the owner not to just let his horse die, but to try GenoMed's treatment, which costs $10 a day.

Within 72 hours, the horse was fully recovered.

West Nile virus encephalitis affects horses more severely than people, and the odds of recovery are slimmer. Dr. Bean feels that GenoMed's treatment made the difference, and is now calling for a wider trial of GenoMed's approach in horses.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "I'm delighted that Dr. Bean has managed to cure a second horse with presumed WNV using our approach. I'm hoping our treatment finally gets a fair trial this year."

GenoMed's treatment success rate for WNV encephalitis in people is currently 87% (20 of 23 patients improved rapidly). A small case series involving the company's first 8 patients was published in a peer-reviewed medical journal in 2004.

About GenoMed

Anyone can download the human protocol for West Nile virus for free from GenoMed's website,, at any time. Horse owners are encouraged to contact Dr. Moskowitz or Dr. Bean directly (see contact information above) to discuss specific medications and dosing.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext